Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$1.1 billion.

  • Regenxbio's Retained Earnings fell 2031.78% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 2031.78%. This contributed to the annual value of -$932.1 million for FY2024, which is 3221.09% down from last year.
  • Regenxbio's Retained Earnings amounted to -$1.1 billion in Q3 2025, which was down 2031.78% from -$996.9 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Retained Earnings registered a high of -$161.2 million during Q4 2021, and its lowest value of -$1.1 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$580.3 million (2023), whereas its average is -$607.5 million.
  • In the last 5 years, Regenxbio's Retained Earnings skyrocketed by 4422.43% in 2021 and then tumbled by 17386.19% in 2022.
  • Regenxbio's Retained Earnings (Quarter) stood at -$161.2 million in 2021, then plummeted by 173.86% to -$441.6 million in 2022, then plummeted by 59.67% to -$705.0 million in 2023, then plummeted by 32.21% to -$932.1 million in 2024, then dropped by 13.72% to -$1.1 billion in 2025.
  • Its Retained Earnings stands at -$1.1 billion for Q3 2025, versus -$996.9 million for Q2 2025 and -$926.1 million for Q1 2025.